{"denoms":[{"counts":[{"groupId":"BG000","value":"301"},{"groupId":"BG001","value":"307"},{"groupId":"BG002","value":"608"}],"units":"Participants"}],"groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"BG000","title":"Enfortumab Vedotin 1.25 mg/kg"},{"description":"Participants received either 75 mg/m\\^2 docetaxel by IV infusion over approximately 1 hour or 320 mg/m\\^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m\\^2 paclitaxel by IV infusion over approximately 3 hours on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"BG001","title":"Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.11","value":"66.52"},{"groupId":"BG001","spread":"9.93","value":"66.81"},{"groupId":"BG002","spread":"9.53","value":"66.67"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"138"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"470"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"53"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"230"},{"groupId":"BG001","value":"238"},{"groupId":"BG002","value":"468"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"87"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"200"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"159"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"314"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"89"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"244"}]}],"title":"ECOG PS=0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"181"},{"groupId":"BG001","value":"183"},{"groupId":"BG002","value":"364"}]}],"title":"ECOG PS=1"}],"description":"ECOG PS was measured on 6 point scale 0-Fully active, able to carry on all pre-disease performance without restriction\n\n1. Restricted in physically strenuous activity but ambulatory \\& able to carry out work of a light or sedentary nature\n2. Ambulatory \\& capable of all self-care but unable to carry out any work activities.Up \\& about more than 50% of waking hours\n3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours\n4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair\n5. Dead Participants were categorized based on ECOG PS 0 or 1","paramType":"NUMBER","title":"ECOG PS","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"208"},{"groupId":"BG001","value":"212"},{"groupId":"BG002","value":"420"}]}],"title":"Liver Metastasis=No"},{"categories":[{"measurements":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"188"}]}],"title":"Liver Metastasis=Yes"}],"description":"Participants were categorized based on liver metastasis (yes or no).","paramType":"NUMBER","title":"Liver Metastasis","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"255"}]}],"title":"Western Europe"},{"categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"87"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"266"}]}],"title":"Rest of the World"}],"description":"Participants were categorized based on region western europe, US and rest of the world.","paramType":"NUMBER","title":"Region","unitOfMeasure":"participants"}],"populationDescription":"The full analysis set (FAS) consisted of all participants who were randomized."}